Adinazolam (brand name Deracyn), with its CAS registry number 37115-32-5, has its IUPAC name of ({12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaen-3-yl}methyl)dimethylamine. For being a benzodiazepine derivative, it possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties.

Following are the detailed information of Adinazolam:
1). Indication of Adinazolam: For the treatment of anxiety and status epilepticus.
2). Pharmacodynamics of Adinazolam: Adinazolam is a benzodiazepine derivative used to treat anxiety, status epilepticus, and for sedation induction and anterograde amnesia. Adinazolam binds with high affinity to the GABA benzodiazepine receptor complex. Considerable evidence suggest that the central pharmacologic/therapeutic actions of alprazolam are mediated via interaction with this receptor complex.
3). Mechanism of action: Adinazolam binds to peripheral-type benzodiazepine receptors which interact allosterically with GABA receptors. This potentiates the effects of the inhibitory neurotransmitter GABA, increasing the inhibition of the ascending reticular activating system and blocking the cortical and limbic arousal that occurs following stimulation of the reticular pathways.